A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

NCT03357952 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab
DRUG: JNJ-63723283

Sponsor

Janssen Research & Development, LLC